The Philadelphia Phillies and Asplundh raised $800,004 for ALS research and care during ALS Awareness Night on June 9, 2025.

Usnoflast is an orally available small molecule that's designed to reduce inflammation, a key contributor to nerve cell ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Experimental drug Ulefnersen offers hope for rare, early-onset Amyotrophic lateral sclerosis (ALS) in clinical trials.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

New research shows that people who take certain psychiatric medications may be more likely to develop amyotrophic lateral ...

The Phillie Phanatic has been known to bust some pretty impressive moves over the years, from choreographed skits on the ...

UC Irvine researchers conducted a study to better understand the molecular basis of amyotrophic lateral sclerosis (ALS), a ...

Experimental drug Ulefnersen shows potential in halting and even reversing symptoms in patients with FUS- Amyotrophic lateral sclerosis (ALS) mutation One patient regained full motor function ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Amyotrophic lateral sclerosis (ALS) is a progressive disease that causes severe weakness due to progressive degeneration of a specific set of motor nerves in the spinal cord. People with ALS will ...

Corcept Therapeutics' dazucorilant failed the primary ALS trial goal but showed improved survival outcomes and a safe profile ...